Evidence map›Paper›PMID 27493884›Full record

ArticleEuropean thyroid journal2016

Comparison of Early Total Thyroidectomy with Antithyroid Treatment in Patients with Moderate-Severe Graves' Orbitopathy: A Randomized Prospective Trial.

Murat Faik Erdoğan, Özgür Demir, Reyhan Ünlü Ersoy, Kamile Gül, Berna İmge Aydoğan, Ziynet Alphan Üç, Türkan Mete, Sibel Ertek, Uğur Ünlütürk, Bekir Çakır and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in European thyroid journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Current concepts regarding Graves' orbitopathy.Journal of internal medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Murat Faik ErdoğanDepartment of Endocrinology and Metabolic Diseases, Ankara University Medical Faculty, Ankara, Turkey.
Özgür DemirDepartment of Endocrinology and Metabolic Diseases, Ankara University Medical Faculty, Ankara, Turkey.
Reyhan Ünlü ErsoyDepartment of Endocrinology and Metabolic Diseases, Yıldırım Beyazıt University Medical Faculty, Ankara, Turkey.
Kamile GülDepartment of Endocrinology and Metabolic Diseases, Yıldırım Beyazıt University Medical Faculty, Ankara, Turkey.
Berna İmge AydoğanDepartment of Endocrinology and Metabolic Diseases, Ankara University Medical Faculty, Ankara, Turkey.
Ziynet Alphan ÜçDepartment of Endocrinology and Metabolic Diseases, Ankara Training and Research Hospital, Ankara, Turkey.
Türkan MeteEndocrinology and Metabolic Diseases, Ankara Numune Training and Research Hospital, Ankara, Turkey.
Sibel ErtekDepartment of Endocrinology and Metabolic Diseases, Ufuk University Medical Faculty, Ankara, Turkey.
Uğur ÜnlütürkDepartment of Endocrinology and Metabolic Diseases, Ankara University Medical Faculty, Ankara, Turkey.
Bekir ÇakırDepartment of Endocrinology and Metabolic Diseases, Yıldırım Beyazıt University Medical Faculty, Ankara, Turkey.
Yalçın AralDepartment of Endocrinology and Metabolic Diseases, Ankara Training and Research Hospital, Ankara, Turkey.
Serdar GülerEndocrinology and Metabolic Diseases, Ankara Numune Training and Research Hospital, Ankara, Turkey.
Sevim GüllüDepartment of Endocrinology and Metabolic Diseases, Ankara University Medical Faculty, Ankara, Turkey.
Demet ÇorapçıoğluDepartment of Endocrinology and Metabolic Diseases, Ankara University Medical Faculty, Ankara, Turkey.
Selçuk DağdelenDepartment of Endocrinology and Metabolic Diseases, Hacettepe University Medical Faculty, Ankara, Turkey.
Gürbüz ErdoğanDepartment of Endocrinology and Metabolic Diseases, Ufuk University Medical Faculty, Ankara, Turkey.
Ankara University · TRAnkara Yıldırım Beyazıt University · TRUfuk University · TRAnkara Numune Eğitim ve Araştırma Hastanesi · TRMinistry of Health · TRHacettepe University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe optimal therapeutic choice for Graves' hyperthyroidism in the presence of moderate-severe Graves' orbitopathy (GO) remains controversial.

objectivesWe aimed to compare GO course in patients with moderate-severe GO treated with early total thyroidectomy (TTx) versus antithyroid drug (ATD) regimens, in a prospective, randomized manner.

methodsForty-two patients with moderate-severe GO were enrolled. A total of 4.5 g of pulse corticosteroids were given intravenously to all patients before randomization. Patients in the first group were given TTx, whereas patients in the second group were treated with ATDs. TSH was kept between 0.4 and 1 mIU/l. The clinical course of GO was evaluated with proptosis, lid aperture, clinical activity score (CAS), and diplopia.

resultsEighteen and 24 patients were randomized to the TTx and ATD groups, respectively. Thyroid autoantibodies decreased significantly, and there were significant improvements in proptosis, lid aperture, and CAS in the TTx group. While in the ATD group the decrement in thyroid autoantibodies was not significant, there were significant improvements in proptosis and CAS. When the TTx group was compared with the ATD group, anti-TPO, anti-Tg, and TSH-receptor antibodies were significantly decreased in the TTx group (p < 0.01), but there was no significant difference with respect to proptosis, lid aperture, CAS, and diplopia between the two groups during a median (min.-max.) follow-up period of 60 months (36-72).

conclusionAlthough no definitive conclusions could be drawn from the study, mainly due to limited power, early TTx and the ATD treatment regimens, followed by intravenous pulse corticosteroid therapy, seemed to be equally effective on the course of GO in this relatively small group of patients with moderate-severe GO during a median (min.-max.) follow-up period of 60 months (36-72).

Indexed as

Antithyroid treatmentGraves’ orbitopathyTotal thyroidectomy

Identifiers

PMID27493884
PMCPMC4949371
OpenAlexW2344548375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.